Anti-GOLGB1 (Giantin) Antibody

Our Anti-GOLGB1 (Giantin) chicken polyclonal primary antibody from Aves Labs is produced in-house. It detects human GOLGB1 (Giantin), and is affinity-purified IgY. It is great for use in IHC and ICC.

Product Specifications

Background

GOLGB1, also known as Giantin, is a protein associated with the Golgi apparatus, playing a key role in maintaining its structural integrity and facilitating vesicle trafficking between the endoplasmic reticulum and the Golgi. Discovered within the context of Golgi apparatus research initiated by Camillo Golgi in 1898, the molecular cloning and sequencing of the GOLGB1 gene in the early 1990s allowed detailed studies of its structure and function, revealing its role in stacking Golgi cisternae and influencing various cell signaling pathways. Functional studies, including knockdown and knockout experiments (Satoh et al 2019), have demonstrated GOLGB1’s importance in maintaining Golgi integrity. A myriad of diseases are associated with Golgi dysfunction, including neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s, as well as cancer and congenital disorders of glycosylation (Lan etc al, 2016) . In time, GOLGB1 (Giantin) could potentially serve as a therapeutic target for many of these conditions.

Short Description

Our Anti-GOLGB1 (Giantin) chicken polyclonal primary antibody from Aves Labs is produced in-house. It detects human GOLGB1 (Giantin), and is affinity-purified IgY. It is great for use in IHC and ICC.

Synonyms

Golgin B1, GCP372, GOLIM1, GCP, Macrogolgin, Golgi Integral Membrane Protein 1, Golgin Subfamily B Member 1

Other Statements

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.

Gene Name

GOLGB1

Host

Chicken

Species Reactivity

Human

Reactivity

Human

Immunogen

Synthetic peptide

Immunogen Type

Human

Target

Giantin

Clonality

Polyclonal

Isotype

IgY

Conjugation

Unconjugated

Applications

ICC, IHC

Field of Research

Apoptosis Cell Signaling Neurodegenerative Disease Alzheimer's Disease Parkinson's Disease Amyotrophic Lateral Sclerosis (ALS) Oncoproteins Vesicle Trafficking/Fusion

Assay Type

Primary Antibody

Assay Protocol

Eggs from hens hyperimmunized with target were used to prepare an IgY fraction which was then subjected to antigen-specific affinity purification

Concentration

200 µg/mL

Format

Affinity-Purified IgY

Form

Affinity-Purified IgY

Buffer

Phosphate-buffered (10 mM) isotonic (0.9%, w/v) saline (“PBS, " pH 7.2) with sodium azide (0.02%, w/v) added as a preservative.

Molecular Weight

376 kDa

Precautions

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.

Shipping Conditions

Ice Packs

Storage Conditions

Store at 4°C in the dark. Under these conditions, the antibodies should have a shelf life of at least twelve months, provided they remain sterile. For longer term storage, aliquot and freeze to avoid freeze-thaw of the antibody.

Shelf Life

12 months from receipt of product

IHC Dilution

1:100-1:500

Specificity

No cross-reactivity reported

Pre Treatment

Eggs from hens hyperimmunized with target were used to prepare an IgY fraction which was then subjected to antigen-specific affinity purification

Target Description

GOLGB1, also known as Giantin, is a protein associated with the Golgi apparatus, playing a key role in maintaining its structural integrity and facilitating vesicle trafficking between the endoplasmic reticulum and the Golgi. Discovered within the context of Golgi apparatus research initiated by Camillo Golgi in 1898, the molecular cloning and sequencing of the GOLGB1 gene in the early 1990s allowed detailed studies of its structure and function, revealing its role in stacking Golgi cisternae and influencing various cell signaling pathways. Functional studies, including knockdown and knockout experiments (Satoh et al 2019), have demonstrated GOLGB1’s importance in maintaining Golgi integrity. A myriad of diseases are associated with Golgi dysfunction, including neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s, as well as cancer and congenital disorders of glycosylation (Lan etc al, 2016). In time, GOLGB1 (Giantin) could potentially serve as a therapeutic target for many of these conditions.